← LeaderboardsInvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Novomedix, Inc.
San Diego, CA
$11,058,738
Total funding
13
Grants
Funding over time
peak $3.3M · FY2007–25$5M$3.8M$2.5M$1.3M$0
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$11,058,738 · 13
By mechanism
R44$3,959,666 · 2
R43$3,267,059 · 8
N44$2,977,013 · 1
SB1$500,000 · 1
N43$355,000 · 1
Investigators at Novomedix, Inc.
InvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Exposure= the full size of every grant they're on ($1M each).
Rising Stars
First grant in the last 5 yrs
Emerging Leaders
6–10 yrs in
Not enough data
All-Time
Most funded here, all years
Largest grants
NOVOMEDIX TRANSITION TO PHASE II - THERAPEUTICS SBIR CONTRACTSBIR PHASE II - ENHANCED OVERALL SURVIVAL IN HIGH-RISK PEDIATRIC SOLID TUMORS USING A NOVEL ORAL SMALL MOLECULE$2,977,013
N44 · FY2025 · CA
Novel small molecules for protection against doxorubicin cardiotoxicity in TNBC$1,062,913
R44 · FY2022 · HL
Novel small molecules for protection against doxorubicin cardiotoxicity in TNBC$930,592
R44 · FY2023 · HL
The optimization of compounds that selectively inhibit protein synthesis for the$833,819
R44 · FY2013 · CA
The optimization of compounds that selectively inhibit protein synthesis for the$792,608
R44 · FY2012 · CA
Discovery and Development of Compounds to Enhance b-cell Number and Function$516,697
R43 · FY2007 · DK
Definitive (GLP) Toxicity and Toxicology Studies for a Novel Small Molecule for Protection Against Cardiotoxicity in Triple Negative Breast Cancer$500,000
SB1 · FY2024 · HL
Discovery and Development of Compounds to Enhance b-cell Number and Function$482,697
R43 · FY2008 · DK
Novel small molecules for protection against doxorubicin cardiotoxicity in TNBC$375,001
R43 · FY2019 · HL
Novel Therapy for Protection against Diabetes and its Complications in Ischemic Heart Disease$375,000
R43 · FY2021 · HL
SBIR CONCEPT AWARD TO NOVOMEDIX- NOVEL SMALL MOLECULES FOR THE TREATMENT OF RHABDOMYOSARCOMA$355,000
N43 · FY2022 · CA
The optimization of compounds that selectively inhibit protein synthesis for the$339,734
R44 · FY2014 · CA
Arthrofibrosis control using small molecule inhibitors of interleukin-11$314,362
R43 · FY2025 · AR
Novel oral small molecules for progressive pulmonary fibrosis$306,872
R43 · FY2024 · HL
Optimization of compounds that selectively inhibit protein synthesis for the trea$300,236
R43 · FY2010 · CA
Novel antifibrotic small molecules for the treatment of heart failure$300,000
R43 · FY2016 · HL
Development of novel small molecule drugs for the treatment of high risk B-ALL$202,398
R43 · FY2012 · CA
Development of novel small molecule drugs for the treatment of high risk B-ALL$93,796
R43 · FY2013 · CA